BioNxt Solutions

Press Release: BioNxt Solutions Unveils Accelerated 90‐Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti‐Aging Expansion BioNxt Solutions (CSE: BNXT | OTC PINK: BNXTF | FSE: BXT) is proud to unveil key milestones that will shape the next 90 days and beyond: 🔬 Global Patent Filings Completed We’ve successfully secured national-level patents in major markets including the United States, Canada, Europe, Australia, and Japan, following a positive review from the European Patent Office. This solidifies our foundation for commercializing sublingual treatments for autoimmune diseases like Multiple Sclerosis (MS), Myasthenia Gravis (MG), Lupus Nephritis (LN), and Rheumatoid Arthritis (RA). 👩⚕️ Human Bioequivalence Study for MS Treatment Our lead product, BNT23001 — a sublingual thin-film Cladribine for MS — is entering its human bioequivalence study. This pivotal step brings us closer to offering patients a more efficient and user-friendly alternative to existing MS therapies. 🧬 Expansion into the $93B+ Longevity & Anti-Aging Market BioNxt is advancing proprietary sublingual and oral drug products aimed at slowing ovarian aging, extending fertility,and promoting healthy aging. As the longevity sector rapidly grows, we’re positioning ourselves at the forefront of this transformative market. BioNxt is committed to pushing the boundaries of what’s possible in bioscience. Stay tuned for updates as we embark on this exciting new chapter! 📄 Read the full press release: https://lnkd.in/e2GG2nAD

PRESS RELEASE: BioNxt Solutions Accelerates R&D with Move to Gen-Plus GmbH & Co. KG Laboratory in Munich, Germany We are thrilled to announce a significant milestone in BioNxt Solutions’ journey toward advancing innovative drug delivery systems and next-generation therapeutics. Starting March 1, 2025, BioNxt will transition its cutting-edge research and development activities to the Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany—one of Europe’s leading biotech hubs. This move opens new doors for innovation, collaboration, and accelerated progress in our mission to deliver transformative therapies that address unmet medical needs. With access to Gen-Plus’ state-of-the-art facilities, including 1,000 square meters of GMP-compliant lab space and advanced technologies, we are poised to: ✅ Enhance R&D capabilities for advanced drug delivery systems ✅ Foster impactful collaborations with leading biotech firms and research institutions ✅ Accelerate the development of therapies targeting neurodegenerative diseases, autoimmune conditions, and more As our CEO, Hugh Rogers, shared: "This transition is both strategic and timely, unlocking new possibilities for innovation and reinforcing our mission to deliver transformative therapies for patients worldwide." BioNxt is committed to pushing the boundaries of what’s possible in bioscience. Stay tuned for updates as we embark on this exciting new chapter! 📄  Read the full press release: https://lnkd.in/ePhR6sqc

PRESS RELEASE: BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP This milestone reinforces our commitment to driving next-generation healthcare solutions for neurodegenerative diseases and beyond. Our proprietary delivery platforms — including sublingual, thin-film, and transdermal patches — are shaping the future of modern medicine. 💡 Why it matters: Stronger IP protection means stronger market positioning, enhanced competitive edge, and increased value for our stakeholders. 📄 Read the full press release: https://lnkd.in/dQAZzDbE

PRESS RELEASE: BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment 📄 Read the full press release: https://lnkd.in/eGg5Uqqc #BioNxt #HealthcareInnovation #DrugDelivery #MultipleSclerosisTreatment #Cladribine

PRESS RELEASE: BioNxt Solutions announces the development of a sublingual thin-film technology for Semaglutide, a widely used therapeutic for Type 2 diabetes and obesity. Our innovative approach aims to address limitations of injectable formats, offering a needle-free, user-friendly alternative to enhance patient outcomes and accessibility. 📄 Read the full press release: https://lnkd.in/eeWW78Ph #BioNxt #HealthcareInnovation #DrugDelivery #Semaglutide

🚀 Exciting Developments at BioNxt Solutions! We’re pleased to share the latest update on our enhanced sublingual product development pipeline, featuring innovative therapies for autoimmune diseases and longevity. 🧬 These advancements highlight our commitment to leveraging cutting-edge drug delivery technologies to improve bioavailability, patient compliance, and treatment outcomes. At BioNxt Solutions, we are dedicated to transforming patient care by addressing unmet medical needs with next-generation solutions. 📢 Read the full press release to learn more: https://lnkd.in/ezENvKx9 #BioNxtSolutions #NextGenDrugDelivery